Business Wire: Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT) inhibition in human cancers at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Mass., November 5 – 9, 2015. Among the presentations are important new data on the critical role played by EZH2 in Non-Hodgkin Lymphoma (NHL). Epizyme’s lead compound, tazemetostat, is a first-in-class EZH2 inhibitor currently being studied in relapsed or refractory B-cell NHL and advanced solid tumors.
Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.
Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.